Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

A new research paper shows that, in some ways, U.S. prescription drug spending is not necessarily all that high.

Researchers reviewed the clinical characteristics of patients taking GLP-1 receptor agonists who develop NAION.

Patients taking a GLP-1 for diabetes have a lower risk for AF at 3 years than those on other medications, report ...

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

Data were included for 262 adults with a body mass index greater than or equal to 27kg/m2 who were initiated on liraglutide or semaglutide. HealthDay News — Glucagon-like peptide-1 receptor ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research ...

GLP-1 drugs are increasingly used to treat obesity in adults. They can also be used in children from the age of 12 and clinical trials have shown children lose 5-16% of their body weight after a ...

These side effects may include: GLP-1 agonists are approved for people with type 2 diabetes to manage their blood sugar levels, and some are approved for weight loss. Let’s take a look at the ...